Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation.
Sallah S, Husain A, Nguyen NP
Blood Coagul Fibrinolysis 2004;15(7):577-582.
Review by M. Aldouri
An algorithm to reduce allogenic red blood cell transfusions for major orthopedic surgery.
Slappendel R, Dirksen R, Weber EW, van der Schaaf DB
Acta Orthop Scand 2003;74(5):569-575.
Review by
The use of recombinant factor VIIa in children with inherited platelet function disorders.
Almeida AM, Khair K, Hann I, Liesner R
Br J Haematol 2003;121(3):477-481.
Review by Aldouri M
Use of recombinant factor Vlla (NovoSeven((R))) to reduce postoperative bleeding after total hip arthroplasty in a patient with cirrhosis and thrombocytopenia.
Slappendel R, Huvers FC, Benraad B, Novakova I, van Hellemondt GG
Anesthesiology 2002;96(6):1525-1527.
Review by
Ongoing NovoSeven((R)) trials.
Erhardtsen E
Intensive Care Med 2002;28(Suppl 2):S248-S256.
Review by Aldouri M
Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta.
Kastrup M, von Heymann C, Hotz H, et al.
Ann Thorac Surg 2002;74(3):910-912.
Review by
Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: A pilot study.
Lynn M, Jerokhimov I, Jewelewicz D, et al.
J Trauma 2002;52(4):703-707.
Review by
Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.
An excellent study about the use of AT III in septic patients. Carefully conducted study: the description in the method section is outstanding. It is... Read More
Recombinant activated factor VII for adjunctive hemorrhage control in trauma.
Martinowitz U, Kenet G, Segal E, et al.
J Trauma 2001;51(3):431-438.
Review by M. Aldouri
Recombinant activated factor VII (RFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices.
This is a new open-label study, which showed efficacy of rFVIIa in normalising prothrombin time and effective control of bleeding esophageal varices in cirrhotic patients,... Read More
Recombinant activated factor VII (RFVIIa): Characterization, manufacturing, and clinical development.
Jurlander B, Thim L, Klausen NK, et al.
Semin Thromb Hemostasis 2001;27(4):373-383.
Review by M. Aldouri
NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.
Sitemap
Contact us
- secretary@nataonline.com
-
NATA
Rue de l’Industrie 24
1040 Bruxelles - VAT: 0781668659